Abstract
P-glycoprotein (PGP), the product of the MDR1 gene, is a transmembrane active efflux pump for a variety of carcinogens and cytostatics. It has been suggested that MDR1 polymorphisms contribute to the variability in cancer risk and therapeutic outcome. We examined the relevance of C3435T polymorphism in relation to breast cancer susceptibility, clinical and pathological characteristics of breast carcinoma, the therapeutic response and hematologic toxicities after anthracycline-based chemotherapy. A significant association between allele frequencies and histological type, stage and histological grade was observed (P=0.024, 0.014, 0.006, respectively, χ2-test or Fisher's exact test). We also found significantly higher (P=0.019, χ2-test) T allele frequency in breast cancer patients (n=221) than in controls (n=113). A significantly enhanced therapeutic outcome after neoadjuvant therapy (n=38; P=0.021, Fisher's exact test) and longer time to progression after anthracycline-based chemotherapy (n=102; P=0.049, log-rank test) were observed in CC homozygotes. However, no significant association between hematologic toxicities and C3435T polymorphism was detectable.
Similar content being viewed by others
References
Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P . Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581–592.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71–96.
Lester J . Breast cancer in 2007: incidence, risk assessment, and risk reduction strategies. Clin J Oncol Nurs 2007; 11: 619–622.
Fossland VS, Stroop JB, Schwartz RC, Kurtzman SH . Genetic issues in patients with breast cancer. Surg Oncol Clin N Am 2009; 18: 53–71.
Stearns V, Davidson NE, Flockhart DA . Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics J 2004; 4: 143–153.
Robert J, Le Morvan V, Smith D, Pourquier P, Bonnet J . Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 2005; 54: 171–196.
Zhou SF . Structure, function and regulation of p-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008; 38: 802–832.
Leslie EM, Deeley RG, Cole SP . Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005; 204: 216–237.
Kerb R . Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006; 234: 4–33.
Fromm MF . The influence of MDR1 polymorphisms on p-glycoprotein expression and function in humans. Adv Drug Deliv Rev 2002; 54: 1295–1310.
Leonessa F, Clarke R . ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 2003; 10: 43–73.
Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473–3478.
Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV et al. A ‘silent’ polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315: 525–528.
Siegsmund M, Brinkmann U, Scháffeler E, Weirich G, Schwab M, Eichelbaum M et al. Association of the p-glycoprotein transporter MDR1C3435T polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002; 13: 1847–1854.
Leschziner GD, Andrew T, Pirmohamed M, Johnson MR . ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 2007; 7: 154–179.
Ferguson LR, De Flora S . Multiple drug resistance, antimutagenesis and anticarcinogenesis. Mutat Res 2005; 591: 24–33.
Zhou SF . Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008; 38: 802–832.
Kurzawski M, DroŸdzik M, Suchy J, Kurzawski G, Białecka M, Górnik W . Polymorphism in the p-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur J Clin Pharmacol 2005; 61: 389–394.
Jamroziak K, Mlynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 2004; 72: 314–321.
Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002; 62: 4955–4962.
DeBruin LS, Josephy PD . Perspectives on the chemical etiology of breast cancer. Environ Health Perspect 2002; 110: 119–128.
Turgut S, Yaren A, Kursunluoglu R, Turgut G . MDR1 C3435T polymorphism in patients with breast cancer. Arch Med Res 2007; 38: 539–544.
Tatari F, Salek R, Mosaffa F, Khedri A, Behravan J . Association of C3435T single-nucleotide polymorphism of MDR1 gene with breast cancer in an Iranian population. DNA Cell Biol 2009; 28: 259–263.
Gervasini G, Carrillo JA, Garcia M, San JC, Cabanillas A, Benitez J . Adenosine triphosphate-binding cassette B1 (ABCB1) (multidrug resistance 1) G2677T=A gene polymorphism is associated with high risk of lung cancer. Cancer 2006; 107: 2850–2857.
Stanulla M, Schäffeler E, Arens S, Rathmann A, Scharauder A, Welte K et al. GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia. Int J Hemato 2005; 81: 39–44.
Miller KL, Kelsey KT, Wiencke JK, Moghadassi M, Miike R, Liu M et al. The C3435T polymorphism of MDR1 and susceptibility to adult glioma. Neuroepidemiology 2005; 25: 85–90.
Gerlach JH, Kartner N, Bell DR, Ling V . Multidrug resistance. Cancer Surv 1986; 5: 25–46.
Kafka A, Sauer G, Jaeger C, Grundmann R, Kreienberg R, Zeillinger R et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 2003; 22: 1117–1121.
Rodrigues FFO, Santos RE, Melo MB, Silva MALG, Oliveira AL, Rozenowicz RL et al. Correlation of polymorphism C3435T of the MDR-1 gene and the response of primary chemotherapy in women with locally advanced breast cancer. Genet Mol Res 2008; 7: 177–183.
Klimecki WT, Futscher BW, Grogan TM, Dalton WS . P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994; 83: 2451–2458.
Oselin K, Nowakowski-Gashaw I, Mrozikiewicz PM, Wolbergs D, Pahkla R, Roots I . Quantitative determination of MDR1 mRNA expression in peripheral blood lymphocytes: a possible role of genetic polymorphisms in the MDR1 gene. Eur J Clin Invest 2003; 33: 261–267.
Acknowledgements
We thank the reviewers for their constructive reviews and helpful comments. This research project was supported by the Ministry of Health of the Slovak Republic (grant No. 2005/46-VOUKE-01) and by the Slovak Grant Agency for Science (VEGA grant No. 1/2282/05 and 1/3372/06).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cizmarikova, M., Wagnerova, M., Schonova, L. et al. MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J 10, 62–69 (2010). https://doi.org/10.1038/tpj.2009.41
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/tpj.2009.41
- Springer Nature Limited
Keywords
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.